BiostealthAI® Extends TCS Patent Portfolio with Hong Kong Grant as OEM Integration Programme Advances

LONDON, UK, September 28, 2026 - BiostealthAI® has secured a Hong Kong patent grant covering its Touchable Cardiovascular Surfaces technology, extending the international reach of the company’s foundational intellectual property for physiological sensing through everyday touch surfaces.

The grant establishes BiostealthAI’s patent position in Hong Kong as the company continues to advance the engineering and commercial infrastructure for deployment of Touchable Cardiovascular Surfaces.

Touchable Cardiovascular Surfaces, or TCS, is an architecture for embedding physiological sensing into surfaces that users already touch during ordinary interaction. Rather than requiring a dedicated wearable or separate sensing accessory, TCS is designed to enable compatible device surfaces to acquire cardiovascular signals while preserving their primary user-interface function.

BiostealthAI is advancing the engineering infrastructure required for OEM integration and deployment of TCS. Current development includes the middleware and integration framework that connects the sensing architecture with host systems, supports controlled handling of physiological data, and provides the validation and platform-adaptation foundation required for practical OEM implementation.

BiostealthAI continues selective technical and commercial engagement with industry stakeholders on TCS integration and licensing pathways.